Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 10/20 | 0.35 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040926 | 0.87 | ACHE (0.39) | ACHEMAOBHTR2CCA1CA2 | |
| SCHEMBL30917566 | 0.80 | S100A4 (0.37) | MAOBCYP19A1HTR2C | |
| SCHEMBL31040873 | 0.80 | TERT (0.39) | HTR2CMEN1KMT2ACA1CA2 | |
| SCHEMBL18474155 | 0.75 | HTR2C (0.38) | ACHEHTR2CCA1CA2 | |
| SCHEMBL30917688 | 0.75 | ALDH1A1 (0.44) | ACHEMEN1KMT2ACA1CA2 | |
| SCHEMBL9463700 | 0.74 | ACHE (0.42) | ACHEMAOBCYP19A1MEN1KMT2A | |
| SCHEMBL7566810 | 0.74 | ACHE (0.54) | ACHEMAOBCYP19A1HTR2CCA1 | |
| SCHEMBL17193929 | 0.72 | HTR2C (0.45) | ACHEHTR2CCA1CA2 | |
| SCHEMBL27527067 | 0.71 | ACHE (0.47) | ACHEMAOBHTR2CKMT2ACA1 | |
| SCHEMBL31040901 | 0.70 | PBRM1 (0.43) | HTR2CMEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070134-A | Use of PRMT5 inhibitors in the treatment of tumors or cancers | 上海湃隆生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4592289-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-13 | — | — | US | disclosed |
| US-12173002-B2 | PRMT5 inhibitors and methods of use | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-12-24 | — | — | US | disclosed |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173002-B2 | PRMT5 inhibitors and methods of use | PRMT5, PRMT1, PRMT7 | ACHE 834/4885MAOB 3496/4885FABP6 2929/4885 |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT7 | ACHE 1095/4885MAOB 3061/4885FABP6 4137/4885 |
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT1, PRMT5, PRMT6 | ACHE 1086/4885MAOB 3907/4885FABP6 3672/4885 |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT3 | ACHE 880/4885MAOB 3700/4885FABP6 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.